Indian pharma companies have started developing their own versions of Novo Nordisk’s top-selling weight-loss medicine Wegovy (semaglutide), hoping for a piece of the multibillion-dollar obesity market.
Tag Archive for: obesity
The company said it is already making manufacturing investments for orforglipron, its next-generation oral weight-loss candidate that recently moved into Phase III development.
The popularity of a new generation of weight-loss medicines is inspiring a growing number of drugmakers to pursue paths emulating Eli Lilly’s (LLY.N) highly-effective Zepbound, but Amgen is taking a unique approach.
According to the FDA, Lilly’s Mounjaro is available only in limited quantities through early March 2024.
The biotech is taking a synergistic approach to obesity with two muscle-preserving antibodies set to enter a Phase II study in mid-2024 in combination with existing incretin-based treatments.
Animal and early-stage human trial data for Amgen’s experimental obesity drug published in a medical journal showed that it promoted significant weight loss with an acceptable safety profile, the company said on Monday.
Novo Nordisk will target launches of its mega popular obesity shot Wegovy in markets where it already has strong sales of its older weight-loss drug Saxenda, CEO Lars Fruergaard Jorgensen said, as it faces growing competition from U.S. rival Eli Lilly.
Stringent regulation, manufacturing costs and absence of price control contribute to high GLP-1 agonist costs in the U.S. Patients could go to other countries for cheaper treatment.
The persistent shortage of genuine glucagon-like peptide 1 receptor agonist products has led to an increase in fake versions, the World Health Organization warned on Monday.
According to Spiegel magazine, Lilly is in talks with the German government to try to end a ban on the public health system paying for weight-loss treatments.
